Piper Jaffray analyst Danielle Brill told investors in a research note that data from Sage Therapeutics’ ongoing trial with 217 in postpartum depression will be an important inflection point for the company in 1Q19 and says she remains bullish ahead of the data. The analyst, who has an Overweight rating and $206 price target on Sage shares, says she is “comfortable” that 217’s MOA and PK profiles are very closely related to brex and it should achieve similar anti-depressant effects in the ongoing pivotal PPD trial.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.